European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
37604067
DOI
10.1016/j.ejca.2023.113254
PII: S0959-8049(23)00356-8
Knihovny.cz E-zdroje
- Klíčová slova
- Basal cell carcinoma, Classification, Destructive therapy, Electrochemotherapy, Gorlin syndrome, Guidelines, Hedgehog inhibitors, Immunotherapy, Photodynamic therapy, Radiation therapy, Surgical therapy, Topical therapy,
- MeSH
- bazocelulární karcinom * diagnóza terapie MeSH
- imunoterapie MeSH
- konsensus MeSH
- lidé MeSH
- nádory kůže * diagnóza terapie MeSH
- proteiny hedgehog MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- proteiny hedgehog MeSH
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from European Association of Dermato-Oncology (EADO), European Dermatology Forum, European Society for Radiotherapy and Oncology (ESTRO), Union Européenne des Médecins Spécialistes, and the European Academy of Dermatology and Venereology developed updated recommendations on diagnosis and treatment of BCC. BCCs were categorised into 'easy-to-treat' (common) and 'difficult-to-treat' according to the new EADO clinical classification. Diagnosis is based on clinico-dermatoscopic features, although histopathological confirmation is mandatory in equivocal lesions. The first-line treatment of BCC is complete surgery. Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites. Topical therapies and destructive approaches can be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial and low-risk nodular BCCs. Management of 'difficult-to-treat' BCCs should be discussed by a multidisciplinary tumour board. Hedgehog inhibitors (HHIs), vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCC. Immunotherapy with anti-PD1 antibodies (cemiplimab) is a second-line treatment in patients with a progression of disease, contraindication, or intolerance to HHI therapy. Radiotherapy represents a valid alternative in patients who are not candidates for or decline surgery, especially elderly patients. Electrochemotherapy may be offered when surgery or radiotherapy is contraindicated. In Gorlin patients, regular skin examinations are required to diagnose and treat BCCs at an early stage. Long-term follow-up is recommended in patients with high-risk BCC, multiple BCCs, and Gorlin syndrome.
1st Department of Dermatology Aristotle University Thessaloniki Greece
Aix Marseille University Dermatology and Skin Cancer Department APHM Marseille France
Centre for Dermatooncology Department of Dermatology Eberhard Karls University Tuebingen Germany
Coimbra Hospital and Universitary Centre Coimbra Portugal
Department of Biotechnological and Applied Clinical Sciences University of L'Aquila L'Aquila Italy
Department of Dermatology and Venereology University Hospital Center Zagreb Croatia
Department of Dermatology Erasme Hospital Université Libre de Bruxelles Brussels Belgium
Department of Dermatology Faculty of Medicine Military Medical Academy Belgrade Serbia
Department of Dermatology Instituto Valenciano de Oncologia Valencia Spain
Department of Dermatology Medical University of Vienna Austria
Department of Dermatology Skin Cancer Center Ruhr University Bochum 44791 Bochum Germany
Department of Dermatology University Hospital Ghent Ghent Belgium
Department of Dermatology University Hospital Zurich and University Zurich Switzerland
Department of Dermatology University of Kiel Kiel Germany
Department of Dermatology Venereology and Allergology University Hospital Frankfurt Germany
Department of Dermatovenereology 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Oncology Odense University Hospital Denmark
Dermatology Clinic University of Trieste Trieste Italy
Dermatology Department Saint Louis Hospital Paris France
Dermatology Medicine School University of Seville University Hospital Virgen Macarena Seville Spain
Citace poskytuje Crossref.org